10x Genomics (TXG) Operating Expenses (2018 - 2026)

10x Genomics' Operating Expenses history runs 9 years deep, the most recent figure standing at $123.2 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 14.88% year-over-year to $123.2 million; the TTM figure through Mar 2026 stood at $483.3 million (down 19.37% YoY), while the FY2025 annual figure was $504.9 million, down 17.1% from the prior year.
• Operating Expenses came in at $123.2 million for Q1 2026 at 10x Genomics, down from $132.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $190.3 million in Q3 2023 to a low of $95.0 million in Q2 2025.
• A 5-year average of $145.6 million and a median of $146.0 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 35.28% in 2023 and sank 34.94% in 2025, its largest moves.
• 10x Genomics' Operating Expenses stood at $142.5 million in 2022, then increased by 19.98% to $171.0 million in 2023, then slipped by 5.95% to $160.8 million in 2024, then decreased by 17.54% to $132.6 million in 2025, then decreased by 7.06% to $123.2 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $123.2 million, $132.6 million, and $132.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison